Literature DB >> 29269157

Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine.

Stephen A Kaba1, Christopher P Karch2, Labdhi Seth1, Karen M B Ferlez1, Casey K Storme1, Danielle M Pesavento1, Paige Y Laughlin1, Elke S Bergmann-Leitner1, Peter Burkhard3, David E Lanar4.   

Abstract

To eliminate the problems associated with the use of extraneous adjuvants we have designed a Self-Assembling Protein Nanoparticle (SAPN) containing epitopes from the Plasmodium falciparum circumsporozoite protein (PfCSP) (designated FMP014) and portions of the TLR5 agonist flagellin (designated FMP014D0D1) as an intrinsic adjuvant. By combining different molar ratios of FMP014 to FMP014D0D1 monomers before self-assembly, we generated multiple nanoparticles and investigated their biophysical characteristics, immunogenicity and protective efficacy. Immunization with the construct formulated with the ratio 58:2 of FMP014 to FMP014D0D1 had the highest protective efficacy against a challenge with a transgenic P. berghei sporozoite expressing PfCSP. Increasing the proportion of flagellin per particle resulted in an inverse relationship with levels of both antibody titers and protection. The cytokine profiles of the various immunization groups were evaluated and quantitative amounts of the cytokines IL-2, IFN-γ, IL-12/p70 (Th1); IL4, IL5 (Th2); TNF-α, IL1β, IL-6, KC/GRO (pro-inflammatory), and IL-10 (immunomodulatory) were measured. The relationship of the cytokines to each other revealed a strong immunomodulatory effect depending on the proportion of flagellin in the construct. Our results demonstrate that SAPNs with flagellin may be a promising strategy for the development and delivery of a safe vaccine for infectious diseases. Published by Elsevier Ltd.

Entities:  

Keywords:  Flagellin; Immune-profiling; Malaria; Nanoparticle; Plasmodium falciparum; Protection; Self-assembling protein nanoparticle; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 29269157     DOI: 10.1016/j.vaccine.2017.12.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Structural analysis of PpSP15 and PsSP9 sand fly salivary proteins designed with a self-cleavable linker as a live vaccine candidate against cutaneous leishmaniasis.

Authors:  Mahya Sadat Lajevardi; Tahereh Taheri; Elham Gholami; Negar Seyed; Sima Rafati
Journal:  Parasit Vectors       Date:  2022-10-19       Impact factor: 4.047

2.  A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection.

Authors:  Valentina Bernasconi; Karin Norling; Inta Gribonika; Li Ching Ong; Sabina Burazerovic; Nagma Parveen; Karin Schön; Anneli Stensson; Marta Bally; Göran Larson; Fredrik Höök; Nils Lycke
Journal:  Mucosal Immunol       Date:  2020-08-17       Impact factor: 7.313

Review 3.  Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

Authors:  Lampouguin Yenkoidiok-Douti; Christopher M Jewell
Journal:  ACS Biomater Sci Eng       Date:  2020-01-12

4.  SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.

Authors:  M Gordon Joyce; Wei-Hung Chen; Rajeshwer S Sankhala; Agnes Hajduczki; Paul V Thomas; Misook Choe; William Chang; Caroline E Peterson; Elizabeth Martinez; Elaine B Morrison; Clayton Smith; Aslaa Ahmed; Lindsay Wieczorek; Alexander Anderson; Rita E Chen; James Brett Case; Yifan Li; Therese Oertel; Lorean Rosado; Akshaya Ganesh; Connor Whalen; Joshua M Carmen; Letzibeth Mendez-Rivera; Christopher Karch; Neelakshi Gohain; Zuzana Villar; David McCurdy; Zoltan Beck; Jiae Kim; Shikha Shrivastava; Ousman Jobe; Vincent Dussupt; Sebastian Molnar; Ursula Tran; Chandrika B Kannadka; Michelle Zemil; Htet Khanh; Weimin Wu; Matthew A Cole; Debra K Duso; Larry W Kummer; Tricia J Lang; Shania E Muncil; Jeffrey R Currier; Shelly J Krebs; Victoria R Polonis; Saravanan Rajan; Patrick M McTamney; Mark T Esser; William W Reiley; Morgane Rolland; Natalia de Val; Michael S Diamond; Gregory D Gromowski; Gary R Matyas; Mangala Rao; Nelson L Michael; Kayvon Modjarrad
Journal:  bioRxiv       Date:  2021-05-10

5.  A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus.

Authors:  Jianping Li; Zeinab H Helal; Christopher P Karch; Neha Mishra; Theodore Girshick; Antonio Garmendia; Peter Burkhard; Mazhar I Khan
Journal:  PLoS One       Date:  2018-09-14       Impact factor: 3.240

6.  A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria.

Authors:  Kirsty L Wilson; Dodie Pouniotis; Jennifer Hanley; Sue D Xiang; Charles Ma; Ross L Coppel; Magdalena Plebanski
Journal:  Front Immunol       Date:  2019-03-15       Impact factor: 7.561

Review 7.  Nano-biotechnology: a new approach to treat and prevent malaria.

Authors:  Khaista Rahman; Shahid Ullah Khan; Shah Fahad; Ming Xian Chang; Aqleem Abbas; Wasim Ullah Khan; Lutfur Rahman; Zaheer Ul Haq; Ghulam Nabi; Dilfaraz Khan
Journal:  Int J Nanomedicine       Date:  2019-02-21

8.  Glycosylation of the HIV-1 Env V1V2 loop to form a native-like structure may not be essential with a nanoparticle vaccine.

Authors:  Christopher P Karch; Gary R Matyas; Peter Burkhard; Zoltan Beck
Journal:  Future Virol       Date:  2019-01-10       Impact factor: 1.831

Review 9.  Vaccination With Sporozoites: Models and Correlates of Protection.

Authors:  Yun Shan Goh; Daniel McGuire; Laurent Rénia
Journal:  Front Immunol       Date:  2019-06-05       Impact factor: 7.561

10.  Novel malaria vaccines.

Authors:  Matthew B Laurens
Journal:  Hum Vaccin Immunother       Date:  2021-08-04       Impact factor: 4.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.